ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

SNG Synairgen Plc

4.675
0.155 (3.43%)
25 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.155 3.43% 4.675 4.35 5.00 - 25,623 16:35:16
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 0 -17.65M -0.0876 -0.52 9.1M
Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. The last closing price for Synairgen was 4.52p. Over the last year, Synairgen shares have traded in a share price range of 3.65p to 10.62p.

Synairgen currently has 201,374,975 shares in issue. The market capitalisation of Synairgen is £9.10 million. Synairgen has a price to earnings ratio (PE ratio) of -0.52.

Synairgen Share Discussion Threads

Showing 4001 to 4023 of 99175 messages
Chat Pages: Latest  163  162  161  160  159  158  157  156  155  154  153  152  Older
DateSubjectAuthorDiscuss
16/4/2020
17:40
Well one good point is that if it appeared in the current sites that SNG001 was having detrimental effects, they wouldn’t be setting up new sites
peachie 74
16/4/2020
17:35
hxxps://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(20)30858-8.pdf
talk2dubya
16/4/2020
17:12
based on the fact they are still recruiting and time to analyse results, I would imagine Nobby's guesstimate of when results will be known is reasonably accurate.
potts650
16/4/2020
17:09
Good stuff. So there are at least 4 sites which are recruiting now Southampton, Leicester, Birmingham and Manchester. As I have said before it is vital to get all 7 sites up and running as quickly as possible so that the patients can be recruited rapidly.
nobbygnome
16/4/2020
17:03
Good find Likya
141jaffa
16/4/2020
16:58
1st patient
likya123
16/4/2020
16:23
Ascending rising channel lower target of 62.2p hit earlier and now rising into close.
Tomorrow we rise towards 80p+ back into the continued ascending channel pattern, unless ofcourse we get a blockbuster RNS.

likya123
16/4/2020
16:13
BM - should I go about ramping SNG over on the NSCI board ? No I won’t, because I am not a complete bell.
talk2dubya
16/4/2020
16:09
Call me a prophet. It appears the MM's are short of stock
vitec
16/4/2020
16:07
Next movement will be up
vitec
16/4/2020
16:04
NetScientific plc (AIM: NSCI), the transatlantic healthcare IP commercialisation Group, today announces that its portfolio company PDS Biotechnology Corporation ("PDS") (Nasdaq: PDSB) announced today an expanded infectious disease pandemic development program, including novel vaccines for COVID-19 and universal influenza, in addition to its previously announced tuberculosis development collaboration with Farmacore Biotechnology.

PDS Biotech's products combine its novel Versamune(R) technology with custom-designed, disease-specific proteins to induce both neutralizing antibody and killer (CD8+) T-cell responses, which when co-induced are more powerful in fighting disease than either alone. This proven Versamune(R) mechanism, combined with a favorable safety profile, provides a strong rationale to expand the development of Versamune(R)-based products beyond its initial series of cancer immunotherapies to add potentially transformative vaccines to protect and fight against infectious agents, including COVID-19, influenza, and tuberculosis.

bmnsa
16/4/2020
15:59
From lse board...


Has anyone seen this? 



I thought it was interesting in explaining that despite a "combination of IFNß with lopinavir/ritonavir against MERS-CoV improved pulmonary function but did not significantly educe virus replication or lung pathology severity", that IFNß1 appears to be most relevant interferon to treat coronavirus infections.

likya123
16/4/2020
15:48
So how quickly do we think our new ‘IIs’ will be able to dump their stock? I do think we are seeing some PIs rainbow chasing here as well.
talk2dubya
16/4/2020
15:48
NAH - social isolation precludes
toffeeman
16/4/2020
15:45
I think a few of you have been around TPI's house and drinking with him
vitec
16/4/2020
15:44
4-30 close
tialouise
16/4/2020
15:40
80p close imo.
dealer55
16/4/2020
15:33
Don't you mean 60? ):
toffeeman
16/4/2020
15:28
Looks like 70p close
peachie 74
16/4/2020
15:09
Plus they have a 17% share of a promising fibrosis drug which has completed phase I. SNG is far from a one trick pony....
nobbygnome
16/4/2020
15:00
Looking like 60p close
jonnynixon
16/4/2020
14:53
Remember SNG is not purely Covid-19 play. They are also trying to treat COPD & severe asthma, which is why I invested in them.

£50m-£60m mcap for drug companies in trials is not uncommon.

If the trials are successful then the mcap would be many times. If they fail the share price would crash but I doubt it would be nil, given they are likely to continue to find treatments for COPD.

sikhthetech
16/4/2020
14:50
NSCI screaming news

I hope someone took note of my post last evening ?


fanramptastic mate - 15 Apr 2020 - 18:34:35 - 3818 of 3924
Synairgen - a potential cure for Covid 19? - SNG
NSCI

Ichimoku charting

With todays closing share price well above the turbulent KUMO cloud we have achieved breakout and as such should now post a STRONG BULL signal.


Hopefully more of the same tomorrow

fanny

fanramptastic mate
Chat Pages: Latest  163  162  161  160  159  158  157  156  155  154  153  152  Older

Your Recent History

Delayed Upgrade Clock